Personalized immunotherapy to fight deadly brain tumors
April 13, 2023
The University of Cincinnati is enrolling patients in an Imvax study that will test the effectiveness of a personalized vaccine approach to fight deadly brain tumors.
April 13, 2023
The University of Cincinnati is enrolling patients in an Imvax study that will test the effectiveness of a personalized vaccine approach to fight deadly brain tumors.
April 14, 2023
University of Cincinnati Cancer Center researchers will present more than a dozen abstracts at the American Association for Cancer Research Annual Meeting 2023, held in Orlando, Florida, April 14-19, including findings that could advance treatments for head and neck and breast cancers.
April 19, 2023
The University of Cincinnati is one of 50 nationwide trial sites for a new clinical trial testing a new treatment for status epilepticus, the most severe and deadly form of epilepsy.
May 3, 2023
WLWT spoke with the University of Cincinnati's Brandon Foreman about a clinical trial testing a new treatment for status epilepticus, the most severe and deadly form of epilepsy.
April 21, 2023
Local 12 and WCPO highlighted the Imvax trial being hosted at the University of Cincinnati that is testing the effectiveness of a personalized vaccine approach to fight deadly brain tumors.
December 8, 2022
Physics World recognized the University of Cincinnati's first-in-human trial of FLASH radiotherapy as one of the Top 10 Breakthroughs of the Year for 2022.
February 7, 2023
The National Cancer Institute (NCI) has announced an intent to fund research from the University of Cincinnati’s Andrew Waters, PhD, to better understand how to overcome treatment resistance and develop better treatments for KRAS-mutated pancreatic cancer.
February 16, 2023
The University of Cincinnati Cancer Center's Sara Medek and Elizabeth Shaughnessy were featured in a Wall Street Journal article commenting on a recent study that found more older women with low-risk breast cancer could forgo radiation after surgery to avoid further side effects.
September 7, 2022
University of Cincinnati researchers recently published study results in JAMA Otolaryngology showing that administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer did not increase rates of complication during and after surgery.
September 7, 2022
GEN News highlighted recent University of Cincinnati and Cincinnati Children's Hospital Medical Center research on metabolic signatures that help predict breast cancer outcomes and could open avenues for new treatments.